Sept. 13 (Bloomberg) -- Novo Nordisk A/S said a study shows more patients benefit from its diabetes drug Victoza when the medicine is prescribed early in the disease.
Scientists delving into data from an existing study found that 72 percent of those treated early with Victoza met a target of lower blood-sugar levels, compared with 49 percent of those treated late, the Bagsvaerd, Denmark-based drugmaker said in a statement today.
Sales of Victoza, which mimics a hormone called GLP-1 and stimulates natural insulin production, more than quadrupled in the second quarter to 1.25 billion kroner ($229 million).
--Editor: Phil Serafino.
To contact the reporter for this story: Marthe Fourcade at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com